Shawmut Breaks Pan-Mass Challenge Fundraising Goal for Third Year in a Row

0
405
: Team Shawmut pictured (left to right) Patrick Walsh, Shawmut; Dr. Christopher Sweeney, Dana-Farber; Seth Porter, Shawmut; Jim Scarpone, Shawmut; Les Hiscoe, Shawmut; Chris Ryan; patient of Dr. Sweeney

BOSTON – Shawmut Design and Construction participated in the 2016 Pan-Mass Challenge, making it the ninth straight year the firm has partaken in the two-day bike-a-thon. This year, Team Shawmut has raised $137,556 and counting.

For the fifth straight year the money raised will directly support the research being conducted by Dana-Farber’s Dr. Christopher Sweeney.

: Team Shawmut pictured (left to right) Patrick Walsh, Shawmut; Dr. Christopher Sweeney, Dana-Farber; Seth Porter, Shawmut; Jim Scarpone, Shawmut; Les Hiscoe, Shawmut; Chris Ryan; patient of Dr. Sweeney
 Team Shawmut pictured (left to right) Patrick Walsh, Shawmut; Dr. Christopher Sweeney, Dana-Farber; Seth Porter, Shawmut; Jim Scarpone, Shawmut; Les Hiscoe, Shawmut; Chris Ryan; patient of Dr. Sweeney

Team Shawmut included CEO Les Hiscoe and 23 Shawmut employees and friends, including Dr. Sweeney of Dana-Farber Cancer Institute and three of his cancer patients. The team rode from Sturbridge to Provincetown to increase awareness and funding for cancer research and patient care at Dana-Farber Cancer Institute. Shawmut also sponsored the Brewster PMC water stop and staffed it with 20 enthusiastic volunteers who cheered on the riders as they came through.

“Every year it is amazing to see the amount of support our team receives from Shawmut employees,” said Jim shawmut-pan-2Scarpone, director at Shawmut Design and Construction and Team Shawmut captain. “From riding to working at the Shawmut waterstop, the Pan-Mass Challenge always seems to bring out the best in our company.”

Team Shawmut has consistently raised more than $100,000 a year to support Dr. Sweeney’s efforts which have enabled him to create a unique database of cancer specimen that allows his team to find the key causes of incurable cancer, and test a new drug designed to make standard therapies more effective.

Advertisement